Cargando…
Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21–AMPK pathway in mice fed a high fat diet
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is considered to be one of the most common chronic liver diseases across worldwide. Epigallocatechin-3-gallate (EGCG) derived from extract of green tea and is well known for beneficial effects on anti-oxidative, anti-inflammatory, and anti-tumor...
Autores principales: | Zhang, Yuanyuan, Yin, Ruili, Lang, Jianan, Fu, Ying, Yang, Longyan, Zhao, Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006476/ https://www.ncbi.nlm.nih.gov/pubmed/35418153 http://dx.doi.org/10.1186/s13098-022-00823-y |
Ejemplares similares
-
FGF19 subfamily members: FGF19 and FGF21
por: Dolegowska, Katarzyna, et al.
Publicado: (2019) -
FGF19 and FGF21: In NASH we trust
por: Talukdar, Saswata, et al.
Publicado: (2020) -
FGF21 and Cardiac Physiopathology
por: Planavila, Anna, et al.
Publicado: (2015) -
Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012) -
FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
por: Henriksson, Emma, et al.
Publicado: (2020)